Brief primer on clostridium difficile infection costs, reimbursement, and government regulation

Christopher Frei; Grace Lee

doi:10.1310/hpj4802-S14

Brief primer on clostridium difficile infection costs, reimbursement, and government regulation

Christopher Frei, Grace Lee

Research output: Contribution to journal › Article › peer-review

Abstract

Clostridium difficile infection (CDI) is an important, costly, public health problem in the United States. Four economic studies have reported attributable costs of $3,000 to $12,000 per case. There is a great need for comparative-and cost-effectiveness studies of new CDI therapies. Such studies should include direct medical costs, indirect costs, lost opportunity costs, costs associated with disease recurrence, and quality of life assessments to help health care decision makers determine the value of these therapies.

Original language	English (US)
Pages (from-to)	S14-S18
Journal	Hospital Pharmacy
Volume	48
Issue number	2 SUPPL. 1
DOIs	https://doi.org/10.1310/hpj4802-S14
State	Published - Feb 1 2013

Keywords

Clostridium difficile infection
cost of illness
disease state management
health policy
pharmacoeconomics

ASJC Scopus subject areas

Pharmacy
Pharmacology
Pharmacology (medical)

Access to Document

10.1310/hpj4802-S14

Fingerprint Dive into the research topics of 'Brief primer on clostridium difficile infection costs, reimbursement, and government regulation'. Together they form a unique fingerprint.

Cite this

@article{73c70c620c3c4ab183e527181cde5409,

title = "Brief primer on clostridium difficile infection costs, reimbursement, and government regulation",

abstract = "Clostridium difficile infection (CDI) is an important, costly, public health problem in the United States. Four economic studies have reported attributable costs of $3,000 to $12,000 per case. There is a great need for comparative-and cost-effectiveness studies of new CDI therapies. Such studies should include direct medical costs, indirect costs, lost opportunity costs, costs associated with disease recurrence, and quality of life assessments to help health care decision makers determine the value of these therapies.",

keywords = "Clostridium difficile infection, cost of illness, disease state management, health policy, pharmacoeconomics",

author = "Christopher Frei and Grace Lee",

year = "2013",

month = feb,

day = "1",

doi = "10.1310/hpj4802-S14",

language = "English (US)",

volume = "48",

pages = "S14--S18",

journal = "Hospital Pharmacy",

issn = "0018-5787",

publisher = "Facts and Comparisons",

number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Brief primer on clostridium difficile infection costs, reimbursement, and government regulation

AU - Frei, Christopher

AU - Lee, Grace

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Clostridium difficile infection (CDI) is an important, costly, public health problem in the United States. Four economic studies have reported attributable costs of $3,000 to $12,000 per case. There is a great need for comparative-and cost-effectiveness studies of new CDI therapies. Such studies should include direct medical costs, indirect costs, lost opportunity costs, costs associated with disease recurrence, and quality of life assessments to help health care decision makers determine the value of these therapies.

AB - Clostridium difficile infection (CDI) is an important, costly, public health problem in the United States. Four economic studies have reported attributable costs of $3,000 to $12,000 per case. There is a great need for comparative-and cost-effectiveness studies of new CDI therapies. Such studies should include direct medical costs, indirect costs, lost opportunity costs, costs associated with disease recurrence, and quality of life assessments to help health care decision makers determine the value of these therapies.

KW - Clostridium difficile infection

KW - cost of illness

KW - disease state management

KW - health policy

KW - pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=84873554965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873554965&partnerID=8YFLogxK

U2 - 10.1310/hpj4802-S14

DO - 10.1310/hpj4802-S14

M3 - Article

AN - SCOPUS:84873554965

VL - 48

SP - S14-S18

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 2 SUPPL. 1

ER -